Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. 2010

Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
State Key Laboratory of Pollution Control and Resource Reuse, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China.

Two series of thiazolidinone derivatives designing for potential EGFR and HER-2 kinase inhibitors have been discovered. Some of them exhibited significant EGFR and HER-2 inhibitory activity. Compound 2-(2-(5-bromo-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one (12) displayed the most potent inhibitory activity (IC(50)=0.09 microM for EGFR and IC(50)=0.42 microM for HER-2), comparable to the positive control erlotinib. Docking simulation was performed to position compound 12 into the EGFR active site to determine the probable binding model. Antiproliferative assay results indicating that some of the thiazolidinone derivatives own high antiproliferative activity against MCF-7. Compound 12 with potent inhibitory activity in tumor growth inhibition would be a potential anticancer agent.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
January 2016, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
March 2012, Bioorganic & medicinal chemistry,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
August 2016, Molecules (Basel, Switzerland),
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
February 2024, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
January 2023, Pharmaceuticals (Basel, Switzerland),
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
January 2015, Anti-cancer agents in medicinal chemistry,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
August 2022, European journal of medicinal chemistry,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
November 2009, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
April 2021, European journal of medicinal chemistry,
Peng-Cheng Lv, and Chang-Fang Zhou, and Jin Chen, and Peng-Gang Liu, and Kai-Rui Wang, and Wen-Jun Mao, and Huan-Qiu Li, and Ying Yang, and Jing Xiong, and Hai-Liang Zhu
April 2017, European journal of medicinal chemistry,
Copied contents to your clipboard!